ResMed Inc. (RMD) स्टॉक विश्लेषण

कंपनी का अवलोकन

ResMed Inc. operates as a leading developer, manufacturer, distributor, and marketer of medical devices and cloud-based software applications designed to diagnose, treat, and manage respiratory disorders across the United States and international markets. The company functions within the Healthcare sector, specifically serving the Medical Instruments & Supplies industry, where it provides critical solutions for sleep and breathing health needs. In terms of scale, ResMed holds a market capitalization of $32.71B and generates annual revenue of $5.40B while employing 10,600 individuals globally. These valuation and revenue figures indicate that ResMed is a substantial entity with significant market penetration, reflecting its established position as a major player in the respiratory care landscape. The breadth of its operations and the size of its workforce suggest a robust organizational structure capable of sustaining complex supply chains and technological developments in a competitive medical environment.

वित्तीय स्वास्थ्य

The company reports a trailing twelve-month revenue of $5.40B and a net income of $1.49B, supported by an EBITDA of $2.02B, which highlights a robust operational earnings power before financing costs and taxes. The difference between the $5.40B revenue and the $1.49B net income reveals a cost structure that maintains a profit margin of 27.5%, indicating efficient conversion of sales into bottom-line earnings after all expenses are deducted. ResMed demonstrates strong financial flexibility with a free cash flow of $1.42B, a figure that aligns closely with its cash position of $1.42B, suggesting the ability to fund operations and capital expenditures without relying heavily on external financing. The firm's profitability is underscored by a gross margin of 61.5%, an operating margin of 35.2%, and the aforementioned profit margin of 27.5%, all of which point to high-value products and effective cost management in pricing and logistics. Regarding leverage, the company holds $1.42B in cash against $847.72M in debt, resulting in a debt-to-equity ratio of 13.41, which indicates a balance sheet that is conservative in its net debt position despite the high equity multiple. Liquidity is further secured by a current ratio of 3.06, signaling that the company possesses ample short-term assets to cover its current liabilities without strain. Management effectiveness is evidenced by a return on equity of 25.7% and a return on assets of 14.7%, metrics that demonstrate the ability to generate substantial returns on the capital invested by shareholders and the total asset base.

मूल्यांकन आकलन

Valuation metrics show a P/E ratio of 22.17 on a trailing twelve-month basis and a forward P/E of 18.40, implying that the market expects earnings growth that would justify the lower multiple on forward earnings compared to historical performance. The price-to-book ratio stands at 5.16, indicating that the market values the company at a significant premium over its book value, reflecting intangible assets, brand strength, and growth prospects that are not captured on the balance sheet. Alternative valuation measures include a price-to-sales ratio of 6.06 and an EV/EBITDA of 15.84, which collectively suggest that the stock is priced for sustained high-quality growth rather than value recovery. In terms of trading range, the stock has a 52-week high of $293.81 and a 52-week low of $199.92, providing a historical context for volatility and potential entry points relative to the recent trading band. The beta value is recorded at 0.93, which indicates that the stock's price volatility moves in line with the broader market, offering a risk profile that is neither significantly more aggressive nor more defensive than the general equity index.

Growth & Income

Revenue growth over the last year stands at 11.0%, while earnings growth reaches 14.5%, indicating that earnings are expanding at a faster pace than revenue, which implies improvements in operational leverage, pricing power, or margin expansion. As a dividend payer, ResMed offers a dividend yield of 1.1% with a payout ratio of 22.4%, a conservative level that suggests the dividend is highly sustainable given the strong earnings growth and low payout percentage. The combination of double-digit earnings growth and a modest payout ratio allows the company to retain a significant portion of profits for reinvestment in research, development, and market expansion. The overall growth and income profile presents a balance of capital appreciation potential through earnings expansion and modest income generation via a reliable, low-risk dividend stream.